Literature DB >> 27150581

ECL-cell carcinoids and carcinoma in patients homozygous for an inactivating mutation in the gastric H(+) K(+) ATPase alpha subunit.

Reidar Fossmark1,2, Oriol Calvete3,4, Patricia Mjønes2,5, Javier Benitez3,4, Helge L Waldum1,2.   

Abstract

A family with a missense variant of the ATP4A gene encoding the alpha subunit of the gastric proton pump (H(+) K(+) ATPase) has recently been described. Homozygous siblings were hypergastrinemic (median gastrin 486 pM) and had gastric tumours diagnosed at a median age of 33 years. In the current histopathological study, we further characterized the tumours found in the gastric corpus. The tumours had the histological appearance of carcinoids (NET G1 or G2) and were immunoreactive for the general neuroendocrine markers chromogranin A (CgA) and synaptophysin as well as the ECL-cell markers vesicular monoamine transporter 2 (VMAT2) and histidine decarbozylase (HDC). One of the tumours consisted of a NET G2 component, but also had a component with glandular growth, which morphologically was classified as an intestinal type adenocarcinoma. Many glands of the adenocarcinoma contained a large proportion of cells positive for neuroendocrine markers, especially the small vesicle marker synaptophysin and the cytoplasmic enzyme HDC. In conclusion, patients homozygous for an inactivating ATP4A mutation develop gastric ECL-cell carcinoids in their 3rd or 4th decade. The adenocarcinoma may be classified as neuroendocrine with ECL-cell differentiation.
© 2016 APMIS. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Gastric proton pump; carcinoids; gastrin; neuroendocrine tumour; proton pump inhibitors

Mesh:

Substances:

Year:  2016        PMID: 27150581     DOI: 10.1111/apm.12546

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  9 in total

1.  Do Gastric Signet Ring Cell Carcinomas and ECL-Cell Neuroendocrine Tumours Have a Common Origin?

Authors:  Reidar Fossmark; Rune Johannessen; Gunnar Qvigstad; Patricia Mjønes
Journal:  Medicina (Kaunas)       Date:  2022-03-23       Impact factor: 2.948

2.  Case Report: Two Is Not (Always) Better Than One: Pyloric Gland Adenoma of the Gastric Cardia and Concurrent Neuroendocrine Cell Dysplasia Arising From Autoimmune Gastritis.

Authors:  Camilla Guerini; Marco Vincenzo Lenti; Chiara Rossi; Giovanni Arpa; Andrea Peri; Anna Gallotti; Antonio Di Sabatino; Alessandro Vanoli
Journal:  Front Med (Lausanne)       Date:  2022-05-19

Review 3.  Gastrin and Gastric Cancer.

Authors:  Helge L Waldum; Liv Sagatun; Patricia Mjønes
Journal:  Front Endocrinol (Lausanne)       Date:  2017-01-17       Impact factor: 5.555

Review 4.  Not only stem cells, but also mature cells, particularly neuroendocrine cells, may develop into tumours: time for a paradigm shift.

Authors:  Helge L Waldum; Kjell Öberg; Øystein F Sørdal; Arne K Sandvik; Bjørn I Gustafsson; Patricia Mjønes; Reidar Fossmark
Journal:  Therap Adv Gastroenterol       Date:  2018-05-27       Impact factor: 4.409

Review 5.  Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility.

Authors:  Reidar Fossmark; Tom C Martinsen; Helge L Waldum
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

Review 6.  Towards Understanding of Gastric Cancer Based upon Physiological Role of Gastrin and ECL Cells.

Authors:  Helge Waldum; Patricia Mjønes
Journal:  Cancers (Basel)       Date:  2020-11-22       Impact factor: 6.639

Review 7.  Gastritis, Gastric Polyps and Gastric Cancer.

Authors:  Helge Waldum; Reidar Fossmark
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

Review 8.  Proton Pump Inhibitor Use, Hypergastrinemia, and Gastric Carcinoids-What Is the Relationship?

Authors:  Denis M McCarthy
Journal:  Int J Mol Sci       Date:  2020-01-19       Impact factor: 5.923

9.  Hypergastrinemia is associated with an increased risk of gastric adenocarcinoma with proximal location: A prospective population-based nested case-control study.

Authors:  Eivind Ness-Jensen; Erling Audun Bringeland; Fredrik Mattsson; Patricia Mjønes; Jesper Lagergren; Jon Erik Grønbech; Helge Lyder Waldum; Reidar Fossmark
Journal:  Int J Cancer       Date:  2020-11-02       Impact factor: 7.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.